“…Despite the low concentrations of the bumetanide through the central nervous system following systemic administration (Kaila, Price, Payne, Puskarjov, & Voipio, 2014), recent studies indicated that bumetanide is able to control some aspects of neurological and neuropsychological disorders such as epilepsy (Gharaylou et al, 2019), schizophrenia (Rahmanzadeh et al, 2017), autism (James, Gales, & Gales, 2019) and Parkinson disease (Damier, Hammond, & Ben-Ari, 2016). Previous studies have shown that in animal models of spinal cord injury, the use of bumtanide reduces allodynia and hyperalgesia (Kim et al, 2017;Mòdol et al, 2015;Pitcher, Price, Entrena, & Cervero, 2007).…”